Volume 386, Issue 9999, Pages 1156-1164 (September 2015) Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial  Prof Kathy Pritchard-Jones, MD, Christophe Bergeron, MD, Beatriz de Camargo, MD, Marry M van den Heuvel-Eibrink, MD, Tomas Acha, MD, Jan Godzinski, MD, Foppe Oldenburger, MD, Liliane Boccon-Gibod, MD, Prof Ivo Leuschner, MD, Prof Gordan Vujanic, MD, Bengt Sandstedt, MD, Jan de Kraker, MD, Harm van Tinteren, PhD, Norbert Graf, MD  The Lancet  Volume 386, Issue 9999, Pages 1156-1164 (September 2015) DOI: 10.1016/S0140-6736(14)62395-3 Copyright © 2015 Pritchard-Jones et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile AVD=actinomycin plus vincristine plus doxorubicin. AV2=actinomycin plus vincristine only (no doxorubicin). The Lancet 2015 386, 1156-1164DOI: (10.1016/S0140-6736(14)62395-3) Copyright © 2015 Pritchard-Jones et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Kaplan-Meier survival curves for event-free survival and overall survival Data from the intention-to-treat population for event-free survival (A) and overall survival (B) and from the per-protocol population for event-free survival (C) and overall survival (D). EFS=event-free survival. OS=overall survival. Per-protocol population includes patients who had eligible tumour stage and histology according to review pathology, and correctly received their assigned treatment. The Lancet 2015 386, 1156-1164DOI: (10.1016/S0140-6736(14)62395-3) Copyright © 2015 Pritchard-Jones et al. Open Access article distributed under the terms of CC BY Terms and Conditions